Superselective intra-arterial chemotherapy treatment for retinoblastoma: clinical experience from a tertiary referral centre
| Autor: | Ahmet Sarici, Bilge Batu Oto, Osman Kizilkilic |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
genetic structures Retinal Neoplasms medicine.medical_treatment Intra arterial chemotherapy Tertiary Care Centers 03 medical and health sciences 0302 clinical medicine medicine.artery medicine Humans Infusions Intra-Arterial Fluoroscopy Melphalan Survival analysis Retrospective Studies Chemotherapy medicine.diagnostic_test business.industry Retinoblastoma Infant General Medicine medicine.disease eye diseases Surgery Ophthalmology Exact test Ophthalmic artery 030221 ophthalmology & optometry business Complication |
| Zdroj: | Canadian Journal of Ophthalmology. 55:406-412 |
| ISSN: | 0008-4182 |
| DOI: | 10.1016/j.jcjo.2020.04.009 |
| Popis: | Objective To evaluate the treatment outcomes of an alternative retrograde superselective ophthalmic artery catheterization (intra-arterial chemotherapy [IAC]), while treating retinoblastoma patients. Methods A retrospective review of IAC for 21 treatment-naive eyes (21 patients, primary group) and 10 eyes of previously treated 9 patients (secondary group). Statistical analysis was performed using Number Cruncher Statistical System 2007, Kaplan–Meier survival analysis, and Fisher’s exact test. Results Total fluoroscopy time ranged from 3 to 12 minutes. Globe salvage was 71.4% (15/21 eyes) and 80% (8/10 eyes) in the primary and secondary groups, respectively. Globe salvage rates were recorded as 100%, 100%, 70%, and 0% for group B, C, D, and E patients, respectively. Conclusions Retrograde IAC is effective in tumour control with shorter fluoroscopy time and acceptable complication rates both for naive and treated patients. Furthermore, controlling retinoblastoma in advanced group D eyes was efficacious. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect